Genetic diversity of CX3CR1 gene and coronary artery disease: New insights through a meta-analysis

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 8-15

  Apostolakis, Stavros ^a   Amanatidou, Virginia ^a   Papadakis, Emmanouil G ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Coronary artery disease; CX3CR1; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE;

ALLELE; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CELL ACTIVATION; CHEMOTAXIS; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE POOL; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOSITY; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; MONOCYTE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HETEROZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 70350572373     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.044     Document Type: Review

References (27)

1. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
2. Curnock A.P., Logan M.K., and Ward S.G. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105 (2002) 125-136
3. Reape T.J. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
4. Zernecke A., Shagdarsuren E., and Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28 (2008) 1897-1908
5. Apostolakis S., Papadakis G.E., Krambovitis E., and Spandidos D.A. Chemokines in vascular pathology. Int J Mol Med 17 (2006) 691-701
6. Imai T., Hieshima K., Haskell C., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
7. Bazan J.F., Bacon K.B., Hardiman G., et al. A new class of membranebound chemokine with a CX3C motif. Nature 385 (1997) 640-644
8. Wong B.W.C., Wong D., and McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 11 (2002) 332-338
9. Lesnik P., Haskell C.A., and Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111 (2003) 333-340
10. Combadière C., Potteaux S., Gao J.L., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
11. Landsman L., Bar-On L., Zernecke A., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 22 (2009) 963-972
12. Faure S., Meyer L., Costagliola D., et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 (2000) 2274-2277
13. Moatti D., Faure S., Fumeron F., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (2001) 1925-1928
14. McDermott D.H., Fong A.M., Yang Q., et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111 (2003) 1241-1250
15. Daoudi M., Lavergne E., Garin A., et al. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem 279 (2004) 19649-19657
16. Nassar B.A., Nanji A.A., Ransom T.P., et al. Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early-onset coronary artery disease in patients with no classic risk factors. Scand J Clin Lab Invest 68 (2008) 286-291
17. Apostolakis S., Baritaki S., Kochiadakis G.E., Igoumenidis N.E., Panutsopulos D., and Spandidos D.A. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 119 (2007) 63-71
18. Niessner A., Marculescu R., Kvakan H., et al. Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 94 (2005) 1251-1256
19. Rios D.L., Callegari-Jacques S.M., and Hutz M.H. Endothelial nitric oxide synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed coronary atherosclerosis. Clin Chim Acta 362 (2005) 138-146
20. Hattori H., Ito D., Tanahashi N., et al. T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. Neurosci Lett 374 (2005) 132-135
21. Ghilardi G., Biondi M.L., Turri O., Guagnellini E., and Scorza R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke 35 (2004) 1276-1279
22. Gugl A., Renner W., Seinost G., et al. Two polymorphisms in the fractalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis 166 (2003) 339-343
23. Niessner A., Marculescu R., Haschemi A., et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome: a possible implication of fractalkine in inflammatory activation. Thromb Haemost 93 (2005) 949-954
24. McDermott D.H., Halcox J.P., Schenke W.H., et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89 (2001) 401-407
25. Gaunt T.R., Rodríguez S., and Day I.N. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8 (2007) 428
26. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., and Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108 (2003) 2498-2504
27. Apostolakis S., Krambovitis E., Vlata Z., Kochiadakis G.E., Baritaki S., and Spandidos D.A. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and rennin-angiotensin system modulators. Thromb Res 121 (2007) 387-395